Navigation Links
Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
Date:6/8/2012

Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo.

Significant improvements were also seen with UST 45mg and 90mg in ACR50* (24.9% and 27.9% respectively vs 8.7%), in ACR70* (12.2% and 14.2% respectively vs 2.4%) and in DAS28-CRP** responses at week 24 vs placebo (65.9% and 67.6% for UST 45mg and 90mg respectively vs 34.5%). Changes from baseline in HAQ-DI*** at week 24 were also significantly greater in patients treated with UST versus placebo and for a greater proportion of patients these changes were clinically meaningful (≥0.3).

In addition, patients in the UST groups who were affected with enthesitis (n=425) or dactylitis (n=286) at baseline, showed greater improvements at week 24 than those in the placebo groups.

"There are a number of patients with psoriatic arthritis who do not respond to currently available treatment options, including biologic medicines targeting TNF. As physicians, we struggle to manage such people as well as we would like," commented Professor Iain McInnes, lead study author from University of Glasgow, Scotland. "The development of this new medicine is a welcome step forward. These results highlight not only Ustekinumab's efficacy but also its promising safety profile. We look forward now to seeing how it compares in trials with standard treatments."

Safety profiles were similar between the two groups. The proportion of patients suffering from one or more adverse events was 41.8% in the UST group compared to 42% in the placebo group. Infections were the most common adverse event; serious adverse events (>1) were reported in 1.7% UST and 2% placebo of patients.

This double-bind placebo controlled trial followed 615 patients with active PsA (≥5 swollen joint counts and ≥5 tender joint counts; c-reactive protein ≥0.3mg/dL) despite treatment with disease modifying anti-rheumatic drugs (DMARDs) and/or non-steroidal anti inflammatory drugs (NSAIDs). Patients were randomised to UST 45mg, 90mg or placebo at weeks zero, four and 12 weeks thereafter. At week 16, patients with <5% improvement in tender joint counts and swollen joint counts entered blinded early escape (PBO to UST 45mg, UST 45mg to UST 90mg, UST 90mg to UST 90mg). Stable concomitant methotrexate (MTX) use was permitted but not mandated. Nearly half of the patients studied used concomitant MTX at baseline but this did not alter the likelihood of benefit of UST.


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
2. Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo
3. Control of disease activity and biologic treatment increase life expectency in RA patients
4. Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
5. Financial Worries Add to Cancer Patients Burden
6. Caring for patients with fecal incontinence costs more than $4,000 per person each year
7. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
8. ASCO: Younger colon cancer patients have worse prognosis at diagnosis, yet better survival
9. Just do it! not good enough for cancer patients, UR researchers say
10. Skin transplant offers new hope for vitiligo patients
11. Nordic Walking a Winner for Heart Failure Patients, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... (PRWEB) , ... April 22, ... ... Administration of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its ... Heron-Doerr, PROSHRED® Philadelphia specializes in providing information destruction , recycling, ...
(Date:4/21/2017)... ... ... Providing broad access to life-saving drugs and rewarding the innovators who develop ... address this problem. , That was the message from Dana Goldman, PhD, Leonard D. ... of Southern California, who served as the keynote speaker for Western University of Health ...
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a global leader in ... and B-7569 vinyl label materials received certification for the BS5609 British Marine ... remain intact and legible, for use on chemical drums shipped by sea. ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... exciting new partnership with the highly regarded and well renowned Asian distributor, Discovery ... myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, ... today unveiled a new store design to enhance ... of healthier food, health-focused products and expanded beauty ... to help customers discover new offerings. Together with ... next evolution of the customer experience at CVS ...
Breaking Medicine Technology: